In addition to the myriad of new therapeutic agents developed to target NLRP3, fluoxetine (FLX), an FDA-approved drug for treating clinical depression, has been recently identified to bind [24] and inhibit NLRP3 [24,25,26]. The gene discussed is NLRP3; the disease is major depressive disorder.